Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

China flag China · Delayed Price · Currency is CNY
5.11
+0.13 (2.61%)
At close: Jul 3, 2026
Market Cap3.35B -20.2%
Revenue (ttm)150.62M +15.4%
Net Income-201.43M
EPS-0.30
Shares Out 656.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,658,483
Open5.01
Previous Close4.98
Day's Range4.90 - 5.18
52-Week Range4.09 - 10.31
Beta0.38
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment... [Read more]

Sector Healthcare
Founded 2007
Employees 166
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688373
Full Company Profile

Financial Performance

In 2025, SHA:688373's revenue was 141.77 million, an increase of 8.83% compared to the previous year's 130.27 million. Losses were -241.61 million, -45.18% less than in 2024.

Financial Statements